These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6408410)

  • 1. Assessment of MAO inhibitors using postmortem human brain tissue: biochemical and therapeutic implications.
    Reynolds GP; Riederer P
    Mod Probl Pharmacopsychiatry; 1983; 19():255-9. PubMed ID: 6408410
    [No Abstract]   [Full Text] [Related]  

  • 2. Cumulative effects of irreversible MAO inhibitors in vivo.
    Felner AE; Waldmeier PC
    Biochem Pharmacol; 1979 Apr; 28(7):995-1002. PubMed ID: 444293
    [No Abstract]   [Full Text] [Related]  

  • 3. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.
    O'Carroll AM; Fowler CJ; Phillips JP; Tobbia I; Tipton KF
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Apr; 322(3):198-202. PubMed ID: 6408492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of monoamine oxidases. Inhibition of bovine brain MAO in intact mitochondria by tricyclic antidepressant drugs.
    Achee FM; Gabay S
    Biochem Pharmacol; 1979 Apr; 28(7):1197-203. PubMed ID: 444277
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine metabolism in human brain: effect of monoamine oxidase inhibition in vitro by (-)deprenyl and (+) and (-) tranylcypromine.
    Reynolds GP; Riederer P; Rausch WD
    J Neural Transm Suppl; 1980; (16):173-8. PubMed ID: 6776236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain.
    Garrick NA; Murphy DL
    Psychopharmacology (Berl); 1980; 72(1):27-33. PubMed ID: 6781004
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of substrate in the inhibition of rat liver and brain monoamine oxidase.
    Fuller RW
    Arch Int Pharmacodyn Ther; 1968 Jul; 174(1):32-7. PubMed ID: 4386711
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues.
    Celada P; Artigas F
    J Neurochem; 1993 Dec; 61(6):2191-8. PubMed ID: 7504085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of monoamine oxidase inhibitors on some arylalkylamines in rate striatum.
    Philips SR; Boulton AA
    J Neurochem; 1979 Jul; 33(1):159-67. PubMed ID: 572413
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain.
    Paterson IA; Davis BA; Durden DA; Juorio AV; Yu PH; Ivy G; Milgram W; Mendonca A; Wu P; Boulton AA
    Neurochem Res; 1995 Dec; 20(12):1503-10. PubMed ID: 8789614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
    Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM
    Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of central monoamine oxidase by imidazoline2 site-selective ligands.
    Lalies MD; Hibell A; Hudson AL; Nutt DJ
    Ann N Y Acad Sci; 1999 Jun; 881():114-7. PubMed ID: 10415906
    [No Abstract]   [Full Text] [Related]  

  • 15. New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants.
    Murphy DL; Garrick NA; Aulakh CS; Cohen RM
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):37-43. PubMed ID: 6735994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.
    Green AR; Youdim MB
    Br J Pharmacol; 1975 Nov; 55(3):415-22. PubMed ID: 1203627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of deprenyl (selegiline) on intra- and extraneuronal dopamine oxidation.
    Oreland L; Arai Y; Stenström A
    Acta Neurol Scand Suppl; 1983; 95():81-5. PubMed ID: 6428149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of monoamine oxidase by clorgyline and deprenyl in circumventricular structures of rat brain.
    Kinemuchi H; Wakui Y; Arai Y; Kamijo K
    Biochem Pharmacol; 1980 Oct; 29(20):2871-4. PubMed ID: 6776962
    [No Abstract]   [Full Text] [Related]  

  • 19. Cardiovascular effects of (+)- and (-)-tranylcypromine compared to other monoamine oxidase inhibitors.
    Greeff K; Dènes B; Tawfik H
    Mod Probl Pharmacopsychiatry; 1983; 19():220-30. PubMed ID: 6408408
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.